Cargando…

Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. The treatment is challenging and nowadays a comprehensive approach based not only in pharmacological strategies is necessary. Identification and control of comorbidities, non-pharmacological treatment, prevention and ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Millan-Billi, Paloma, Serra, Candela, Alonso Leon, Ana, Castillo, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164236/
https://www.ncbi.nlm.nih.gov/pubmed/30042369
http://dx.doi.org/10.3390/medsci6030059
_version_ 1783359551365447680
author Millan-Billi, Paloma
Serra, Candela
Alonso Leon, Ana
Castillo, Diego
author_facet Millan-Billi, Paloma
Serra, Candela
Alonso Leon, Ana
Castillo, Diego
author_sort Millan-Billi, Paloma
collection PubMed
description Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. The treatment is challenging and nowadays a comprehensive approach based not only in pharmacological strategies is necessary. Identification and control of comorbidities, non-pharmacological treatment, prevention and management of exacerbations as well as other areas of care (social, psychological) are fundamental for a holistic management of IPF. Gastroesophageal reflux, pulmonary hypertension, obstructive sleep apnea, combined with emphysema, lung cancer and cardiovascular involvement are the main comorbidities associated with IPF. Non-pharmacological treatment includes the use of oxygen in patients with rest or nocturnal hypoxemia and other support therapies such as non-invasive ventilation or even a high-flow nasal cannula to improve dyspnea. In some patients, lung transplant should be considered as this enhances survival. Pulmonary rehabilitation can add benefits in outcomes such control of dyspnea, exercise capacity distance and, overall, improve the quality of life; therefore it should be considered in patients with IPF. Also, multidisciplinary palliative care programs could help with symptom control and psychological support, with the aim of maintaining quality of life during the whole process of the disease. This review intends to provide clear information to help those involved in IPF follow up to improve patients’ daily care.
format Online
Article
Text
id pubmed-6164236
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61642362018-10-10 Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis Millan-Billi, Paloma Serra, Candela Alonso Leon, Ana Castillo, Diego Med Sci (Basel) Review Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. The treatment is challenging and nowadays a comprehensive approach based not only in pharmacological strategies is necessary. Identification and control of comorbidities, non-pharmacological treatment, prevention and management of exacerbations as well as other areas of care (social, psychological) are fundamental for a holistic management of IPF. Gastroesophageal reflux, pulmonary hypertension, obstructive sleep apnea, combined with emphysema, lung cancer and cardiovascular involvement are the main comorbidities associated with IPF. Non-pharmacological treatment includes the use of oxygen in patients with rest or nocturnal hypoxemia and other support therapies such as non-invasive ventilation or even a high-flow nasal cannula to improve dyspnea. In some patients, lung transplant should be considered as this enhances survival. Pulmonary rehabilitation can add benefits in outcomes such control of dyspnea, exercise capacity distance and, overall, improve the quality of life; therefore it should be considered in patients with IPF. Also, multidisciplinary palliative care programs could help with symptom control and psychological support, with the aim of maintaining quality of life during the whole process of the disease. This review intends to provide clear information to help those involved in IPF follow up to improve patients’ daily care. MDPI 2018-07-24 /pmc/articles/PMC6164236/ /pubmed/30042369 http://dx.doi.org/10.3390/medsci6030059 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Millan-Billi, Paloma
Serra, Candela
Alonso Leon, Ana
Castillo, Diego
Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
title Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
title_full Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
title_fullStr Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
title_full_unstemmed Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
title_short Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
title_sort comorbidities, complications and non-pharmacologic treatment in idiopathic pulmonary fibrosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164236/
https://www.ncbi.nlm.nih.gov/pubmed/30042369
http://dx.doi.org/10.3390/medsci6030059
work_keys_str_mv AT millanbillipaloma comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis
AT serracandela comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis
AT alonsoleonana comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis
AT castillodiego comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis